Annual Report

Overview

The report states that Piramal Pharma's consolidated FY2022 revenue rose to ₹ 6,559.10 Crores, while the company acquired Hemmo Pharmaceuticals and expanded its subsidiary base. Its CSR obligations were delivered through Piramal Foundation education projects, with Rs. 6.30 Crores spent during the year. Energy initiatives included plant-efficiency projects and a reported 7% renewable-energy purchase at the Ennore site.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: 1 April 2021 – 31 March 2022
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services